Denali Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Denali Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-524	Closed	-$38K	–	476
2023 Q1	$38K	Hold	524	–	–	0.02%	242
2022 Q4	$43K	Hold	524	–	–	0.02%	242
2022 Q3	$50K	Buy	+524	New	+$58.9K	0.02%	209

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Denali Advisors's ATRA Position: Q2 2023 in Review

Denali Advisors sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 524 shares — an estimated $38K sold.

Denali Advisors first reported a position in ATRA in Q3 2022 and held it in 3 quarters. The position peaked at $50K in Q3 2022. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

Denali Advisors reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
Denali Advisors sold 524 Atara Biotherapeutics shares in Q2 2023, an estimated $38K.
Denali Advisors first reported a position in Atara Biotherapeutics in Q3 2022 and held it in 3 quarters.
Denali Advisors's Atara Biotherapeutics position peaked at $50K in Q3 2022.
118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Denali Advisors's 13F filing for Q2 2023, filed 18 Jul 2023.